Free Trial

Context Therapeutics (CNTX) SEC Filings & 10K Form

Context Therapeutics logo
$0.71 +0.01 (+2.08%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$0.72 +0.02 (+2.64%)
As of 05/22/2025 06:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Context Therapeutics SEC Filings

DateFilerForm TypeView
05/15/2025
7:38 AM
Context Therapeutics (Subject)
Deep Track Capital, LP (Filed by)
Form SCHEDULE 13G/A
05/09/2025
12:08 PM
Context Therapeutics (Subject)
FRANKLIN RESOURCES INC (Filed by)
Form SCHEDULE 13G/A
04/09/2025
6:33 AM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
03/20/2025
3:44 PM
Context Therapeutics (Filer)
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
02/28/2025
3:06 PM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/14/2025
9:02 AM
Avidity Partners Management LP (Filed by)
Context Therapeutics (Subject)
Form SCHEDULE 13G/A
02/14/2025
5:27 AM
Context Therapeutics (Subject)
Opaleye Management Inc. (Filed by)
Form SCHEDULE 13G/A
02/12/2025
4:20 PM
Context Therapeutics (Subject)
Lehr Martin A. (Filed by)
Form SCHEDULE 13G/A
01/27/2025
11:55 AM
Context Therapeutics (Subject)
FRANKLIN RESOURCES INC (Filed by)
Form SCHEDULE 13G
01/14/2025
7:36 PM
Context Therapeutics (Issuer)
Pasternak Andy (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
01/14/2025
7:43 PM
Context Therapeutics (Issuer)
Pasternak Andy (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
01/14/2025
4:03 PM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/13/2025
6:37 AM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
01/08/2025
3:07 PM
Context Therapeutics (Subject)
MPM BioImpact LLC (Filed by)
Form SCHEDULE 13G
12/23/2024
8:26 AM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/02/2024
3:20 PM
Context Therapeutics (Filer)
Form 424B5
12/02/2024
3:21 PM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
11/14/2024
11:15 PM
Context Therapeutics (Filer)
Form EFFECT
11/14/2024
3:52 PM
Context Therapeutics (Subject)
GREAT POINT PARTNERS LLC (Filed by)
Form SC 13G/A
11/06/2024
4:08 PM
Context Therapeutics (Subject)
Hudson Bay Capital Management LP (Filed by)
Form SC 13G/A
11/06/2024
3:42 PM
Context Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
09/23/2024
6:33 AM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/17/2024
3:22 PM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/05/2024
7:15 AM
Context Therapeutics (Issuer)
Smith Karen L. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2024
7:01 AM
Context Therapeutics (Issuer)
Walker Luke Nathaniel (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/05/2024
7:04 AM
Context Therapeutics (Issuer)
Walker Luke Nathaniel (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
09/05/2024
7:08 AM
Context Therapeutics (Issuer)
Smith Karen L. (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
09/04/2024
6:34 AM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
08/01/2024
4:15 PM
Context Therapeutics (Issuer)
Dansky Ullmann Claudio (Reporting)
Form 3
Initial statement of beneficial ownership of securities  
08/01/2024
4:18 PM
Context Therapeutics (Issuer)
Dansky Ullmann Claudio (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/24/2024
4:07 PM
Context Therapeutics (Filer)
Form DEFA14A
07/24/2024
3:55 PM
Context Therapeutics (Filer)
Form DEF 14A
07/10/2024
6:33 AM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/14/2024
6:52 AM
Context Therapeutics (Issuer)
Stacey Jennifer Evans (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/14/2024
6:41 AM
BERMAN RICHARD J (Reporting)
Context Therapeutics (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
06/14/2024
6:47 AM
Context Therapeutics (Issuer)
West Linda (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/14/2024
6:50 AM
Context Therapeutics (Issuer)
Kantoff Philip W. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
06/14/2024
6:34 AM
Context Therapeutics (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
06/05/2024
9:45 AM
Context Therapeutics (Subject)
GREAT POINT PARTNERS LLC (Filed by)
Form SC 13G
06/02/2024
11:15 PM
Context Therapeutics (Filer)
Form EFFECT
05/24/2024
6:31 AM
Context Therapeutics (Filer)
Form S-3
Registration statement under Securities Act of 1933  
Think NVDA’s run was epic? You ain’t seen nothin’ yet (Ad)

Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?

Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave.
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:CNTX) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners